Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Historical Holders from Q3 2014 to Q3 2025

Symbol: SAGE
Type / Class: Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
Shares outstanding: 62,650,155
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 26,706
Holdings value: $494,024
% of all portfolios: 0%
Number of holders: 4
Number of sells: -185
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	7.2%		$34,471,350		4,425,077		BlackRock, Inc.	31 Mar 2025
VANGUARD GROUP INC	5.21%	-33.6%	$29,784,114	-$14,339,987	3,265,802	-32.5%	The Vanguard Group	30 Jun 2025
RTW INVESTMENTS, LP	4.9%		$23,388,462		3,002,370		RTW Investments, LP	31 Dec 2024
BB BIOTECH AG	1.9%		$9,180,538		1,178,503		BB Biotech AG	13 Jan 2025
MORGAN STANLEY	1.6%	-82.9%	$7,886,105	-$27,503,802	1,012,337	-77.7%	Morgan Stanley	28 Feb 2025
FMR LLC	0.8%	-84.3%	$3,902,130	-$28,169,341	500,915	-87.8%	FMR LLC	28 Feb 2025

Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	26,706	$494,024	-$445,436,937	$0	$0	$8.94	4
2025 Q2	48,874,647	$445,736,286	-$15,762,130	$4,014,624	$6,863,355	$9.12	190
2025 Q1	51,753,624	$411,497,036	+$29,109,546	$2,477,220	$1,446,105	$7.95	196
2024 Q4	51,167,791	$277,852,513	-$6,197,488	$635,310	$1,445,466	$5.43	173
2024 Q3	51,256,195	$370,077,943	-$24,510,910	$1,508,980	$2,629,417	$7.22	171
2024 Q2	53,511,146	$581,112,272	-$70,089,721	$2,113,356	$8,858,902	$10.86	190
2024 Q1	58,440,998	$1,095,196,207	+$43,391,410	$3,571,644	$3,178,104	$18.74	199
2023 Q4	56,110,184	$1,215,929,511	-$60,792,173	$6,607,093	$10,962,763	$21.67	196
2023 Q3	58,785,676	$1,209,823,569	-$2,528,143	$5,262,306	$12,387,102	$20.58	192
2023 Q2	54,096,461	$2,543,396,226	+$53,758,888	$12,295,480	$17,368,533	$47.02	222
2023 Q1	52,951,870	$2,221,541,781	+$61,109,823	$7,628,328	$12,344,368	$41.96	210
2022 Q4	51,655,406	$1,969,597,318	+$218,675	$3,192,318	$15,767,000	$38.14	200
2022 Q3	51,490,290	$2,016,420,954	+$13,625,356	$3,736,000	$16,099,248	$39.16	182
2022 Q2	51,071,239	$1,649,759,751	+$39,700,428	$6,767,000	$16,028,500	$32.3	188
2022 Q1	49,945,298	$1,653,434,346	-$25,580,877	$17,829,000	$25,038,500	$33.1	190
2021 Q4	50,185,286	$2,135,089,557	+$29,204,332	$28,207,638	$52,534,700	$42.54	201
2021 Q3	49,060,569	$2,173,846,483	-$115,480,957	$29,204,431	$13,252,550	$44.31	215
2021 Q2	50,613,429	$2,875,212,413	-$158,839,086	$109,425,479	$53,443,845	$56.81	246
2021 Q1	53,088,674	$3,974,807,423	-$71,753,377	$83,974,480	$38,218,675	$74.85	254
2020 Q4	53,803,776	$4,654,671,800	+$61,838,572	$39,358,239	$40,749,535	$86.51	244
2020 Q3	53,660,582	$3,277,403,116	-$18,817,366	$18,884,000	$50,390,000	$61.12	224
2020 Q2	54,023,562	$2,247,849,991	+$2,123,337	$15,561,000	$27,781,646	$41.58	207
2020 Q1	55,020,519	$1,580,165,244	-$222,075,767	$11,807,000	$13,294,000	$28.72	213
2019 Q4	55,964,444	$4,040,118,901	-$417,728,404	$82,211,217	$98,025,119	$72.19	256
2019 Q3	58,267,547	$8,175,198,734	+$23,489,599	$110,520,000	$88,003,000	$140.29	273
2019 Q2	58,089,604	$10,632,783,890	+$989,879,978	$139,003,000	$87,957,000	$183.09	265
2019 Q1	56,290,569	$8,953,438,249	+$1,124,287,863	$85,505,000	$107,328,000	$159.05	258
2018 Q4	49,737,058	$4,761,682,266	+$3,495,565	$87,904,000	$121,085,000	$95.79	241
2018 Q3	49,008,712	$6,924,204,711	+$56,782,421	$57,931,000	$55,935,000	$141.25	272
2018 Q2	48,621,395	$7,610,500,125	+$162,362,469	$54,018,000	$54,910,000	$156.53	265
2018 Q1	47,521,631	$7,647,354,047	+$644,797,785	$48,562,000	$55,891,000	$161.07	243
2017 Q4	44,056,451	$7,257,119,465	+$681,492,435	$219,278,000	$274,226,000	$164.71	220
2017 Q3	39,314,584	$2,450,400,062	+$48,577,382	$100,664,000	$55,467,000	$62.3	168
2017 Q2	38,446,334	$3,055,447,026	+$50,629,626	$125,217,000	$157,295,000	$79.64	187
2017 Q1	37,871,607	$2,691,023,691	+$271,054,103	$134,092,000	$46,310,000	$71.07	185
2016 Q4	36,733,208	$1,875,786,404	-$50,072,012	$30,833,000	$24,931,000	$51.06	161
2016 Q3	37,761,752	$1,738,397,667	+$400,822,533	$20,330,000	$19,171,000	$46.05	150
2016 Q2	30,208,087	$911,383,018	+$28,986,285	$34,658,000	$49,791,000	$30.13	137
2016 Q1	29,073,553	$931,907,546	+$174,147,459	$2,100,000	$2,664,000	$32.06	138
2015 Q4	23,473,499	$1,368,495,352	+$157,290,312	$6,949,000	$4,268,000	$58.3	135
2015 Q3	27,212,732	$1,151,636,509	+$26,731,112	$4,177,000	$9,327,000	$42.32	126
2015 Q2	26,411,389	$1,927,998,498	+$372,239,794	$9,081,000	$3,066,000	$73	120
2015 Q1	21,505,189	$1,080,202,161	+$87,874,721			$50.23	90
2014 Q4	19,746,808	$722,803,309	+$22,868,587			$36.6	71
2014 Q3	18,894,149	$595,167,000	+$595,167,000			$31.5	50